|Drug name||Drugstore||Cash price||Price with RX||Savings % / $|
|Synthroid (Levothyroxine)||CVS pharmacy||$45||$40,81||9% / $4,19|
|Crestor (Rosuvastatin)||Walgreens||$269||$94,87||64% / $174,13|
|Ventolin HFA (Albuterol)||Target CVS||$68||$61,73||9% / $6,27|
|Nexium (Esomeprazole)||Rite Aid||$250||$115,79||53% / $134,21|
|Advair Diskus (Fluticasone)||Kroger pharmacy||$402||$377,38||6% / $24,62|
|Lantus Solostar (Insulin glargine)||Walmart||$447||$391,02||12% / $55,98|
|Vyvanse (Lisdexamfetamine)||Target CVS||$305||$285,21||6% / $19,79|
|Lyrica (Pregabalin)||Kroger pharmacy||$414||$393,9||4% / $20,1|
|Spiriva Handihaler (Tiotropium)||Walmart||$406||$386,31||4% / $19,69|
|Januvia (Sitagliptin)||Rite Aid||$462||$407,55||11% / $54,45|
The world pharmaceutical market has almost tripled over 12 years (from 380 billion in 2001 to 980 billion in 2013). And in 2018 it is already 1300 billion dollars. Growth in the number and aging of the population, increase in the incomes of citizens of some countries (China’s share in market growth is 40%), as well as an increase in the number of new drug groups and affordable generics, will further develop the pharmacy.
The first place for appointments was occupied by the hypolipidemic drug Crestor (rosuvastatin calcium), gaining 21 million appointments in June alone. The company to the manufacturer (AstraZeneca) managed to protect the patent for the drug in the US until January 8, 2016, until July 8, 2016 – in pediatrics. Last year, the US market brought the company exactly half of the revenue from sales of Krestor (about $3.16 billion). Let me remind you that the main competitor of Crestor, Lipitor (Liprimar, Atorvastatin) lost his patent in 2011.
Advair used to treat bronchial asthma and COPD, the company Glaxo Smith Klein. The patent of this drug in the US also ends in 2016. The US market is key to Glaxo, as it provides about 50% of all profits from the sale of Advair (in the US, its cost is $300). Let me remind you that the company is going through hard times in connection with the failure to develop some new drugs.
The third place is taken by the drug all the same AstraZeneca Nexium (Esomeprazole), taken for the treatment of acid-dependent gastrointestinal diseases. The patent ended in 2014. In the same year, Ranbaxy received an exclusive right to manufacture generic in the United States. Soon, the plant Ranbaxy, licensed to produce Esomeprazole, received a ban for the violation of the production process. As a result, the branded drug managed to maintain high sales. Also, AstraZeneca signed a cooperation agreement with TEVA in the production of generics.
Lantus Solostar is an insulin glargine from Sanofi Aventis. The peptide is recombinant insulin that is hardly soluble in a neutral medium. In the formulation Lantus SoloStar, it is entirely soluble, which is provided by acid reaction of the solution for injection (pH 4). After introduction into the subcutaneous fat, the acid reaction of the solution is neutralized, which leads to the formation of micro-precipitates, from which small amounts of insulin glargine are released continuously, providing a predictable effect. SoloSTAR – the name of the syringe-pen, patented by Sanofi.
The Shire is a modern biotechnology company specializing in expensive drugs for rare diseases (the drug for the treatment of hereditary angioedema edema Cynrize is one of the five most expensive drugs in the world).
The drug Vyvanse (Lisdexamfetamine) is the exception to the company’s portfolio, as it is intended for the treatment of children and adults with attention deficit disorder. The number of prescriptions Vyvanse can judge the popularity of this diagnosis – they exceed 10 million/month. It is a prodrug (in the liver an active substance is formed, dexamphetamine is an amphetamine derivative). It is symbolic that the amphetamine derivative, as it were, replaced the Ritalin in the fight against the syndrome of respiratory disorders.
|Drug||Number of appointments (million/month)||Sales per month|